Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application

Jan Damoiseaux*, Judith Potjewijd, Ruben L Smeets, Carolien Bonroy

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The ACR/EULAR classification criteria for systemic sclerosis (SSc) entail three autoantibodies: anti-centromere antibodies (ACA), anti-topoisomerase I antibodies (ATA), and anti-RNA-polymerase III antibodies (ARA). The importance of ACA and ATA in the classification criteria is evidence based, but the diagnostic value is overestimated by clinicians. Fortunately, these autoantibodies are characterized by good agreement between different immuno-assays. Inclusion of ARA, however, is based on limited evidence and is related to limited agreement between different immuno-assays. Harmonization of immuno-assays in terms of interpretation based on likelihood ratio's may improve future classification criteria for SSc and this needs to be achieved by close collaboration between clinicians, laboratory specialists and the diagnostic industry.

Original languageEnglish
Article number100141
Number of pages5
JournalJournal of Translational Autoimmunity
Volume5
DOIs
Publication statusPublished - 2022

Keywords

  • Systemic sclerosis
  • Classification
  • Autoantibodies
  • Harmonization
  • EVIDENCE-BASED GUIDELINES
  • RNA-POLYMERASE-III
  • CLASSIFICATION CRITERIA
  • INTERNATIONAL CONSENSUS
  • IMMUNOLOGICAL TESTS
  • ANTIBODIES
  • VALIDATION
  • PATTERNS
  • COLLEGE
  • SCL-70

Cite this